The Problem
🕐
Too Slow
CT imaging cannot determine response until 3 months into treatment - after multiple costly, potentially harmful cycles.
📈
Pseudoprogression
Tumour flares on imaging can mimic disease progression, causing premature discontinuation in 10% of patients.
💸
Wasted Resources
Only 30% of patients respond to immunotherapy. Ineffective treatment wastes $120K per patient.
Our Solution — Totiomics Response Index (TRI)
A multi-omic, blood-based platform that predicts immunotherapy response at diagnosis using four integrated layers of cfDNA biology.
Layer 1 – Mutation
Ultra-sensitive ctDNA VAF tracking (UMI-based), detects down to 0.01% VAF
Layer 2 – Fragmentomics
Tumour-derived fragment size profiles and nucleosome positioning patterns
Layer 3 – Methylation
Tissue-of-origin deconvolution resolves immune cell vs. tumour cfDNA
Layer 4 – T-cell Signature ★
Novel biomarker (AACR 2024, PR017) from LUD2015-005 trial; first T-cell cfDNA layer for immuno-oncology
🩸 Blood draw (Day 0 / Day 15) → TRI Score (0–100) → Clinical report within 5 business days
Traction & Validation
Trial: durvalumab (anti-PD-L1) + tremelimumab (anti-CTLA-4) + CRT in oesophageal cancer, funded by Ludwig Cancer Research & CRUK.
Market Opportunity
Clinical Trials (TAM)$4.2B
Clinical Diagnostics (TAM)$2.9B
Data Licensing (TAM)$2.1B
Totiomics SAM (Year 5)~$350M
Immuno-oncology global market: $150B by 2030 (CAGR 14.2%) · IO liquid biopsy Dx TAM: ~$2.9B by 2030
Competitive Landscape
| Company |
ctDNA Mut. |
Methylation |
Baseline test |
Multi-omic |
AI-Integrated |
| 🔵 Totiomics | ✓ | ✓ | ✓ | ✓ | ✓ |
| Foundation Medicine / Roche | ✓ | ✗ | ✗ | ✗ | ✗ |
| Guardant Health | ✓ | ✗ | ✗ | ✗ | ✗ |
| Grail (Illumina) | ✗ | ✓ | ✗ | ✗ | ✗ |
| Natera (Signatera) | ✓ | ✗ | ✗ | ✗ | ✗ |
Business Model
Phase 1 · 2026–2028 · Pharma-First
TRI-as-a-service in IO trials · $3k–$5k/patient · 500 patients · Target: $2M ARR
Phase 2 · 2028–2029 · Clinical Lab
CLIA-CAP certified LDT · 2,500 patients/yr · Target: $12M ARR
Phase 3 · 2030+ · IVD & Data
FDA Breakthrough Device · IVD clearance · Data licensing · Target: $50M ARR
Financials
Projected Revenue
Path to profitability: Q4 2029
Use of $8M Seed
Clinical Validation (n=300)25% · $2M
CLIA Lab Build-out25% · $2M
R&D / Algorithm Dev.12.5% · $1M
Team & Operations25% · $2M
Series A trigger (24 months): 3 pharma contracts · patents submitted · CLIA cert · $3M ARR
Team
Ethan Wang, DPhil Candidate
CEO & Co-Founder
Computational biologist. Biomarker discovery and prognostic model development across Johns Hopkins, Harvard, and Oxford.
Branavan Rudran, MBBS, DPhil Candidate
CMO & Co-Founder
Physician-scientist with clinical trial expertise in data-driven patient stratification and medical imaging technologies at Oxford.
Xin Lu, PhD
Academic Advisor
Director, Ludwig Institute of Cancer Research, University of Oxford. Expert in tumour biology and cancer early detection.
Leo Wang, MBA
Financial Advisor
Global Head of EFI at HSBC. Seasoned expert in global markets and AI-driven financial transformation.
Key Milestones
NOW – Phase 1/2 LUD2015-005 complete
Q4 2026 – LOI signed with 2 pharma partners
Q2 2027 – Key patents submitted
Q3 2027 – CLIA lab certification obtained
2028 – FDA Breakthrough Device application
Raising $8M Seed · SAFE Note · $40M Cap · 20% discount for first $2M
Completed Phase 1/2 clinical trial proves cfDNA predicts immunotherapy response at diagnosis. Now deploying that proof into a clinical-grade diagnostic platform and the data asset that defines the next decade of immuno-oncology.
10-50x+ Exit Potential ($400M floor / $2B+ ceiling)
Comparables: Natera $27B · Guardant $11B · Tempus AI $6B at IPO
Ethan Wang, CEO
ethan.wang@totiomics.com
www.totiomics.com